* Aprea Therapeutics Inc reported a quarterly adjusted loss of 58 cents per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of -87 cents. The mean expectation of three analysts for the quarter was for a loss of 63 cents per share. Wall Street expected results to range from -69 cents to -58 cents per share.
* Revenue rose 124.8% to $562.00 thousand from a year ago; analysts expected $50.00 thousand.
* Aprea Therapeutics Inc's reported EPS for the quarter was a loss of 58 cents.
* The company reported a quarterly loss of $3.47 million.
* Aprea Therapeutics Inc shares had fallen by 17.4% this quarter and lost 28.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 21.2% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Aprea Therapeutics Inc is $16.00 This summary was machine generated from LSEG data August 12 at 02:46 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.63 -0.58 Beat
Mar. 31 2024 -0.78 -0.67 Beat
Dec. 31 2023 -0.77 -0.92 Missed
Sep. 30 2023 -1.16 -0.86 Beat
Comments